These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32814344)

  • 1. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
    Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE
    Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The In Situ Structure of Parkinson's Disease-Linked LRRK2.
    Watanabe R; Buschauer R; Böhning J; Audagnotto M; Lasker K; Lu TW; Boassa D; Taylor S; Villa E
    Cell; 2020 Sep; 182(6):1508-1518.e16. PubMed ID: 32783917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.
    Snead DM; Matyszewski M; Dickey AM; Lin YX; Leschziner AE; Reck-Peterson SL
    Nat Struct Mol Biol; 2022 Dec; 29(12):1196-1207. PubMed ID: 36510024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.
    Dederer V; Sanz Murillo M; Karasmanis EP; Hatch KS; Chatterjee D; Preuss F; Abdul Azeez KR; Nguyen LV; Galicia C; Dreier B; Plückthun A; Versees W; Mathea S; Leschziner AE; Reck-Peterson SL; Knapp S
    J Biol Chem; 2024 Jul; 300(7):107469. PubMed ID: 38876305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Biology of LRRK2 and its Interaction with Microtubules.
    Leschziner AE; Reck-Peterson SL
    Mov Disord; 2021 Nov; 36(11):2494-2504. PubMed ID: 34423856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric inhibition of LRRK2, where are we now.
    Soliman A; Cankara FN; Kortholt A
    Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease.
    Herbst S; Lewis PA
    Biochem J; 2021 Jul; 478(14):2945-2951. PubMed ID: 34328508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
    Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ
    Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.
    Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
    Kalogeropulou AF; Purlyte E; Tonelli F; Lange SM; Wightman M; Prescott AR; Padmanabhan S; Sammler E; Alessi DR
    Biochem J; 2022 Sep; 479(17):1759-1783. PubMed ID: 35950872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural analysis of the full-length human LRRK2.
    Myasnikov A; Zhu H; Hixson P; Xie B; Yu K; Pitre A; Peng J; Sun J
    Cell; 2021 Jun; 184(13):3519-3527.e10. PubMed ID: 34107286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides.
    Helton LG; Soliman A; von Zweydorf F; Kentros M; Manschwetus JT; Hall S; Gilsbach B; Ho FY; Athanasopoulos PS; Singh RK; LeClair TJ; Versées W; Raimondi F; Herberg FW; Gloeckner CJ; Rideout H; Kortholt A; Kennedy EJ
    ACS Chem Biol; 2021 Nov; 16(11):2326-2338. PubMed ID: 34496561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal microtubules and proteins linked to Parkinson's disease: a relevant interaction?
    Calogero AM; Mazzetti S; Pezzoli G; Cappelletti G
    Biol Chem; 2019 Aug; 400(9):1099-1112. PubMed ID: 31256059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2: from kinase to GTPase to microtubules and back.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Hilfiker S
    Biochem Soc Trans; 2017 Feb; 45(1):141-146. PubMed ID: 28202667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
    Tasegian A; Singh F; Ganley IG; Reith AD; Alessi DR
    Biochem J; 2021 Oct; 478(19):3555-3573. PubMed ID: 34515301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the Influence of Specific Splicing Events on the Structural Organization of
    Vlachakis D; Labrou NE; Iliopoulos C; Hardy J; Lewis PA; Rideout H; Trabzuni D
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.